Offering guidance for next year, Closure Medical said Thursday morning that it expected a 34 percent increase in revenue.

Closure (Nasdaq: CLSR) said it expected revenues between $45 million and $47 million with net income in the range of $9.7 million to $10.5 million and earnings between 65 cents and 70 cents a share.

The company cited “increased adoption and acceptance” of its Dermabond products, including High Viscosity and ProPen, which were introduced this year. Closure also said it is increasing sales in international markets.